Pricing Strategy

Study in Nigeria
Questionnaire for Physicians (Oncologists, Urologists, Hematologists)
 Pricing Study – Physicians Survey

INTRODUCTION
Welcome and thank you for agreeing to participate in our survey.
IQVIA, a global healthcare insights company, is seeking your opinion about different pricing scenarios for certain brand.
We are conducting this survey on behalf of a pharmaceutical company. Any information presented during the course of
this research is done solely to explore reactions to such information and should be assumed to represent hypotheses
about what can be said about a product. It will not be used to influence decisions outside the research setting. The
information you provide will be treated as confidential and your identity will not be revealed to a third party without your
prior consent.
The survey will take approximately 60 minutes to complete.

Based upon the above, do you agree to proceed with the survey?
 Yes – I consent to participate in the survey - CONTINUE
 No – TERMINATE

Market Research Interview Disclaimer: We are now being asked to pass on to our client details of adverse events that
are mentioned during the course of market research. Although what you say will, of course, be treated in confidence, should
you raise during the discussion an adverse event in a specific patient or a product-specific complaint, we will need to report
this even if it has already been reported by you directly to the company or the regulatory authorities.

In such a situation you will be asked whether you are willing to waive the confidentiality given to you under the Market
Research Codes of conduct specifically in relation to that adverse event. Adverse experience information provided is shared
with regulatory agencies, the sponsoring company's affiliates worldwide, and business partners with whom the sponsoring
company has contractual agreements. Everything else you say during the course of the interview will continue to remain
confidential, and you will still have the option to remain anonymous if you so wish.

[ ] Please check to confirm you have read and understand the above declaration and allow us to re-contact for AE reporting
purpose.

PHYSICIAN SCREENER
S1. Respondent Information – Country
Nigeria Ghana Kenya
Lagos Accra Nairobi 1
Port Harcourt Kumasi Mombasa 2
Kano 3
Abuja 4

S2. Which of the following best describes your primary medical specialty?

Oncologist 1
CONTINUE
Urologist 2

Hematologist 3

Others 98 TERMINATE

S3. In which setting are you mainly active?

[WHOLE NUMBERS ONLY; RANGE 0-100. DO NOT ACCEPT A RANGE]
 Setting Code Percent of Professional Time
General Hospital 1
Teaching Hospital 2
Private hospital 3
Other 4
TOTAL SUM=100%

S4. For how many years have you been in practice?

# of Years in Practice
a. ≥ 3 years  [CONTINUE WITH S5]
b. < 3 years  [Thank and Terminate]

S5. What percentage of time do you currently devote to direct patient care?
| ___ | ___ | ___ | % TERMINATE IF LESS THAN 70%

S6. In a typical month, how many patients do you see or treat across all conditions?
[WHOLE NUMBERS ONLY; RANGE 0-9999. DO NOT ACCEPT A RANGE]

S7. In a typical month, how many patients do you see or treat for Cancer?
[WHOLE NUMBERS ONLY; RANGE 0-9999. DO NOT ACCEPT A RANGE]
TERMINATE IF <50
# of patients seen or treated in a typical month _____#

S8. Please select the brands you are aware of even if you have never prescribed it? (Please select all that apply)
TERMINATE IF RESPONDENT IS NOT AWARE OF ANY BRAND
TERMINATE IF <20
# of patients seen or treated in a typical month _____#

S9. Of the brands that you are aware of, please select the ones that you have ever prescribed to your patients?
(Please select all that apply)
TERMINATE IF RESPONDENT DOES NOT PRESCRIBE ANY BRAND

Brands S8 S9
 
1 Brand 1
 
2 Brand 2
 
3 Brand 2
 
4 Brand 4
 
5 Brand 5
END OF SCREENER
 MAIN QUESTIONNAIRE
PROSTATE CANCER [Oncologists/ Urologists]

Interviewer Scripts: We would now like to progress to understanding the epidemiology for Prostate Cancer and your
perception into affordability level

a. Epidemiology

1. Could you estimate roughly how many prevalent prostate cancer patients exists currently in your country?
(Prompt e.g. per 100 men how many have prostate cancer?)
(Prompt: “As per GBD data source, we saw that prostate cancer prevalence is 12.22/100,000 in Ghana. What is your
feedback? Can you draw an analogy from Ghana? Do you feel it’s underrepresented or overrepresented? What
according to you will be the right number?”)
a. Out of these prevalent patients, how many will be diagnosed?
b. Out of these diagnosed patients, what percentage will be treated? How many with chemotherapy? With
targeted therapies? With combined treatments (chemo + targeted therapies)
c. How would you qualify treatment persistence (people who don’t discontinue treatment) of prostate cancer
patients? Can you provide an estimate?
Proportion of
Proportion of treated
Prevalent prevalent Proportion of diagnosed patient treated
Indication patient who will
patients patient (% to add up to 100%)
continue treatment
diagnosed
Chemo
Targeted therapy
Prostate
Combo chemo/targeted therapies
Cancer
Others
Chemo

2. Of all the diagnosed prostate cancer patients, what is the percentage split between the following stages of
prostate cancer?

% patients
Localized disease
Locally advanced disease
Biochemical recurrence
Advanced non-metastatic (M0) castrate resistant
disease
Metastatic hormone-sensitive disease (mHSPC)
Metastatic castrate resistant disease (mCRPC)
TOTAL SHOULD ADD TO 100%

3. In patients diagnosed with metastatic CRPC, what percentage of patients receive the following?

% patients
Hormonal therapy alone
Hormonal therapy in combination with other
modalities
Chemotherapy alone
Chemotherapy in combination with other modalities
 4. What percentage of the prostate cancer patients seen and treated by you in a typical month falls under the
following line of therapies?

% patients
1st Line of Therapy
2nd Line of Therapy
3rd Line of Therapy and above
TOTAL SHOULD ADD UP TO 100%

b. Affordability Assessment [Oncologist, Urologists]

Interviewer Scripts: We would now like to have your view on a product coming to the market and understanding number of
patients which will be able to afford it.
We will refer to this product as product C (Refer TPP for Product C)
1. Without considering costs, on a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’, how likely are you to
include Product C in your current treatment regimen?

Likelihood of including Product C in current treatment regimen

Indication
( On a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’)
mCRPC/ mHSPC

a. If rated 3 and below, what are the main reasons for low likelihood of adoption/usage of Product A? Probe:
bound by guidelines, estimated cost of therapy, clinical profile, lack of infrastructural support etc.

2. Now thinking about cost of therapy (per month) of Product C,

a. At what cost of therapy would you think that Product C is cheap?
b. At what cost of therapy would you think that Product C is expensive?
c. At what cost of therapy would you think that Product C is so cheap that you could doubt its quality?

At what price point would you think that Product C is so expensive so you would not buy it?
RULES:
i. No two cost of therapies can be the same.
ii. If “cheap” or “expensive” cost of therapy are exceptionally low or high, please ask the respondent to
review and edit their response as appropriate.
iii. "So expensive" will always be the highest cost of therapy.
iv. "So cheap" will always be the lowest cost of therapy.
v. “Expensive" will always be higher than "cheap”

3. Considering different price scenarios, how would your likelihood of prescription change?
(Prompt: Avg. monthly treatment cost will be ~350k-400k Naira)

Out of 10 patients, Out of these, how

Out of these ones,
Product C Annual how many will be many will continue
Indication how many will be
Price (Naira,000s) prescribed one of the treatment
able to afford it?
these drugs? throughout?
5,300
mCRPC/
4,700
mHSPC
4,100
 3,500
2,900
2,300

Hematological Malignancies [Oncologists, Hematologists]

Interviewer Scripts: We would now like to progress to understanding the epidemiology for Hematological Malignancies
including Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL), Chronic lymphocytic leukemia (CLL)/Small lymphocytic
lymphoma (SLL), Waldenström’s Macroglobulinemia (WM), and Marginal zone lymphoma (MZL) and your perception into
affordability level

a. Epidemiology

1. Could you estimate roughly how many prevalent hematological malignancy patients exists currently in your
country? (Prompt e.g. per 100 people how many have some type of hematological malignancy?)
a) Out of these prevalent patients, how many will be diagnosed?
Proportion of prevalent patient
Indication Prevalent patients (%)
diagnosed
Hematological Malignancies

2. Of all the diagnosed Hematological malignancies patients, what is the percentage split between the different
types? (Disease Sub type split to add up to 100%
% patients
A. Multiple Myeloma
B. Lymphoma
- Mantle cell Lymphoma
- Marginal zone lymphoma
- Waldenstrom macroglobulinemia
- Others
C. Leukemia
- CLL
- Others
TOTAL SHOULD ADD TO 100%

a)Now focusing on Multiple myeloma, of all the diagnosed, what will be the treatment split between the
different treatment types?

Proportion of diagnosed patient treated Proportion of treated patient who will

Indication
(% to add up to 100%) continue treatment

Chemo
Targeted therapy
Multiple Myeloma
Combo chemo/targeted therapies:
Others:

b)What percentage of the Multiple myeloma patients seen and treated by you in a typical month falls
under the following line of therapies?
 Lines of therapy % patients
1st Line of Therapy
2nd Line of Therapy
3rd Line of Therapy and above
TOTAL SHOULD ADD UP TO 100%
c) Moving on to lymphoma, of all the diagnosed patients, what will be the percentage split between the
following types?

Proportion of diagnosed patient treated Proportion of treated patient who will

Indication
(% to add up to 100%) continue treatment
Chemo
Mantle cell lymphoma Targeted therapy
(MCL) Combo chemo/targeted therapies
Others
Chemo
Waldenström’s Targeted therapy
Macroglobulinemia (WM) Combo chemo/targeted therapies
Others
Chemo
Marginal zone lymphoma Targeted therapy
(MZL) Combo chemo/targeted therapies
Others

d)What percentage of the Lymphoma cancer patients seen and treated by you in a typical month falls
under the following line of therapies?

% patients
Mantle cell lymphoma Waldenström’s Marginal zone
(MCL) Macroglobulinemia (WM) lymphoma (MZL)
1st Line of Therapy
2nd Line of Therapy
3rd Line of Therapy and above
TOTAL SHOULD ADD UP TO 100 100 100

e)Lastly, focusing on CLL (Chronic lymphocytic leukemia), of all the diagnosed, what will be the
treatment split between the different treatment types?

Proportion of diagnosed patient treated Proportion of treated patient who will

Indication
(% to add up to 100%) continue treatment

Chemo
Chronic lymphocytic Targeted therapy
leukemia Combo chemo/targeted therapies
Others

f) What percentage of the CLL patients seen and treated by you in a typical month falls under the
following line of therapies?
 Lines of therapy % patients
1st Line of Therapy
2nd Line of Therapy
3rd Line of Therapy and above
TOTAL SHOULD ADD UP TO 100%

b. Affordability Assessment [Oncologist, Hematologists]

Interviewer Scripts: We would now like to have your view on a new product coming to the market and understanding
number of patients which will be able to afford it. (Refer TPP for Product D) - Nigeria only
We will refer to this product as product D

1. Without considering costs, on a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’, how likely are you to
include Product D in your current treatment regimen?
Likelihood of including Product D in current treatment regimen
Indication
( On a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’)
Multiple Myeloma (MM)
Mantle cell lymphoma (MCL)

a. If rated 3 and below, what are the main reasons for low likelihood of adoption/usage of Product D? Probe:
bound by guidelines, estimated cost of therapy, clinical profile, lack of infrastructural support etc.

2. Now thinking about cost of therapy (per month) of Product D,

a. At what cost of therapy would you think that Product D is cheap?
b. At what cost of therapy would you think that Product D is expensive?
c. At what cost of therapy would you think that Product D is so cheap that you could doubt its quality?

At what price point would you think that Product D is so expensive so you would not buy it?
RULES:
i. No two cost of therapies can be the same.
ii. If “cheap” or “expensive” cost of therapy are exceptionally low or high, please ask the respondent to
review and edit their response as appropriate.
iii. "So expensive" will always be the highest cost of therapy.
iv. "So cheap" will always be the lowest cost of therapy.
v. “Expensive" will always be higher than "cheap”

3. Considering different price scenarios, how would your likelihood of prescription change?
(Prompt: Avg. monthly treatment cost will be ~600k-1,200k Naira)

Out of 10 patients,
Product D Out of these ones, Out of these, how many will
how many will be
Indication Price how many will be continue the treatment
prescribed one of
(Naira,000s) able to afford it? throughout?
these drugs?
16,000
14,200
Multiple 12,400
Myeloma
(MM) 10,600
8,800
7,000
 7,300
6,500
Mantle cell 5,700
lymphoma
(MCL) 4,900
4,100
3,300

 Now, a second product for 2nd and 3rd line treatment of Multiple myeloma that will be launched in your country.
We will refer to this product as product F (Refer TPP for product F)

1. Without considering costs, on a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’, how likely are you to
include Product F in your current treatment regimen?
Likelihood of including Product F in current treatment regimen
Indication
( On a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’)
2nd line Multiple Myeloma
3rd line Multiple Myeloma (in
combination)
3rd line Multiple Myeloma (monotherapy)

a. If rated 3 and below, what are the main reasons for low likelihood of adoption/usage of Product F? Probe:
bound by guidelines, estimated cost of therapy, clinical profile, lack of infrastructural support etc.

2. Now thinking about cost of therapy (per month) of Product F,

a. At what cost of therapy would you think that Product F is cheap?
b. At what cost of therapy would you think that Product F is expensive?
c. At what cost of therapy would you think that Product F is so cheap that you could doubt its quality?

At what price point would you think that Product F is so expensive so you would not buy it?
RULES:
i. No two cost of therapies can be the same.
ii. If “cheap” or “expensive” cost of therapy are exceptionally low or high, please ask the respondent to
review and edit their response as appropriate.
iii. "So expensive" will always be the highest cost of therapy.
iv. "So cheap" will always be the lowest cost of therapy.
v. “Expensive" will always be higher than "cheap”

3. Considering different price scenarios, how would your likelihood of prescription change?
(Prompt: Avg. monthly treatment cost will be ~2500k-2900k Naira)

Out of 10 patients,
Product F Out of these ones, Out of these, how many will
how many will be
Indication Annual Price how many will be continue the treatment
prescribed one of
(Naira,000s) able to afford it? throughout?
these drugs?
36,000
Multiple 32,500
Myeloma
29,000
25,500
 22,000
18,500

 A product approved for multiple indications including mantle cell lymphoma (MCL), Chronic lymphocytic leukemia
(CLL)/Small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM) and Marginal zone lymphoma
(MZL) that will be launched in your country. (Refer TPP for Product E)
We will refer to this product as product E

1. Without considering costs, on a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’, how likely are you to
include Product E in your current treatment regimen?
Likelihood of including Product E in current treatment regimen
Indication
( On a scale of 1 to 5, where 1 is ‘not likely’ and 5 is ‘very likely’)
Mantle cell lymphoma (MCL)
Chronic lymphocytic leukemia
(CLL)/Small lymphocytic lymphoma
(SLL)
Waldenström’s macroglobulinemia
(WM)
Marginal zone lymphoma (MZL)

a. If rated 3 and below, what are the main reasons for low likelihood of adoption/usage of Product Z? Probe:
bound by guidelines, estimated cost of therapy, clinical profile, lack of infrastructural support etc.

2. Now thinking about cost of therapy (per month) of Product E,

a. At what cost of therapy would you think that Product E is cheap?
b. At what cost of therapy would you think that Product E is expensive?
c. At what cost of therapy would you think that Product E is so cheap that you could doubt its quality?

At what price point would you think that Product E is so expensive so you would not buy it?
RULES:
i. No two cost of therapies can be the same.
ii. If “cheap” or “expensive” cost of therapy are exceptionally low or high, please ask the respondent to
review and edit their response as appropriate.
iii. "So expensive" will always be the highest cost of therapy.
iv. "So cheap" will always be the lowest cost of therapy.
v. “Expensive" will always be higher than "cheap”
vi. “Expensive" will always be higher than "cheap”

3. Considering different price scenarios, how would your likelihood of prescription change?
(Prompt: Avg. monthly cost for CLL/WM will be ~1200k-1300k Naira, MCL/MZL will be ~1600k-1700k Naira)

Out of 10 patients, Out of these, how

Product E price by Out of these ones,
how many will be many will continue
Indication Treatment Duration how many will be
prescribed one of the treatment
(Naira, 000s) able to afford it?
these drugs? throughout?
Chronic 21,000
lymphocytic 19,000
leukemia (CLL)/
Marginal zone 17,000
lymphoma (MZL) 15,000
 13,000
11,000
15,500

13,900
Mantle cell
lymphoma (MCL)/ 12,300
Waldenström’s
macroglobulinemia 10,700
(WM)
9,100

7,500

Note: Median duration of treatment for CLL-17.4 months, MZL-11.7 months, MCL-8.3 months, WM-11.7 months

******Thank you for completing the survey. We appreciate your inputs********